Tag

And in BALANCE-II, 300 patients who had experienced an inadequate response to methotrexate were given one of five doses of the drug for 12 weeks, and significant differences vs placebo on ACR20 were seen for all but the lowest dose group, the company reported. A total of 35% of...

Dublin-based pharmaceutical group Shire said today it had bid Dollars 30 billion (27 billion euros) for US rival Baxalta to form a global biotech company focused on rare diseases. Shire said its unsolicited all-share offer valued each Baxalta share at $45.23, based on August. 3...